{"nctId":"NCT00255190","briefTitle":"Safety and Quality of Life Study of Dexlansoprazole Modified Release Formulation to Treat Heartburn","startDateStruct":{"date":"2006-01"},"conditions":["Gastroesophageal Reflux Disease"],"count":591,"armGroups":[{"label":"Dexlansoprazole MR 60 mg QD","type":"EXPERIMENTAL","interventionNames":["Drug: Dexlansoprazole MR"]},{"label":"Dexlansoprazole MR 90 mg QD","type":"EXPERIMENTAL","interventionNames":["Drug: Dexlansoprazole MR"]}],"interventions":[{"name":"Dexlansoprazole MR","otherNames":["TAK-390MR","Kapidex","Dexilant"]},{"name":"Dexlansoprazole MR","otherNames":["TAK-390MR","Kapidex","Dexilant"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects must have successfully completed either T-GD04-082 (NCT00251745) or T-GD04-083 (NCT00251758) or have a diagnosis of gastroesophageal reflux disease with or without erosive esophagitis.\n\nExclusion Criteria:\n\n* Any condition that may require inpatient surgery during the course of the study.\n* Use of prescription or non-prescription proton pump inhibitors, histamine (H2) receptor antagonists, sucralfate, misoprostol or prokinetics throughout the study.\n* Use of antacids \\[except for study supplied GelusilÂ®\\].\n* Subjects using drugs with significant anticholinergic effects such as tricyclics who cannot stay on a stable dose for 4 weeks prior to dosing and throughout the study.\n* Evidence of uncontrolled systemic disease.\n* Allergy to any proton pump inhibitor including Prilosec, Nexium, Prevacid, or others, any component of dexlansoprazole MR, or Gelusil/antacid.\n* Need to take blood thinners.\n* Need to take more than 12 doses of non-steroidal anti-inflammatory drugs per month.\n* Had cancer (except basal cell cancer of the skin) within 3 years prior to screening.\n* Has other esophageal disease including Barrett's esophagus or strictures requiring dilation.\n* Has had radiation or cryotherapy to the esophagus.\n* Has active gastric or duodenal ulcers within 4 weeks of starting study drug.\n* Has a history of hypersecretory conditions such as Zollinger Ellison Syndrome.\n* History of alcohol abuse.\n* Has acquired immunodeficiency syndrome.\n* Has had acute upper gastrointestinal bleeding within 4 weeks of endoscopy.\n* Received a blood product transfusion within 3 months of taking the first dose of study drug.\n* Has previously participated in another dexlansoprazole MR long-term treatment clinical trial.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Change From Baseline to Month 12 for Hemoglobin Values","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.29","spread":"0.873"},{"groupId":"OG001","value":"-0.05","spread":"0.959"}]}]}]},{"type":"PRIMARY","title":"Mean Change From Baseline to Month 12 for Hematocrit Values","description":"Hematocrit measurement percent is the absolute difference in Hematocrit values, and not percentage difference.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.98","spread":"2.573"},{"groupId":"OG001","value":"-0.93","spread":"3.156"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Month 1 for PAGI-QOL Total Score","description":"Mean overall composite Quality of Life (QOL) score changes were computed in response to 30 questions, each scored 0 (lowest QOL) to 5 (highest QOL). Positive changes from baseline indicate improved QOL.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.54","spread":"0.718"},{"groupId":"OG001","value":"0.54","spread":"0.735"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Month 3 for PAGI-QOL Total Score","description":"Mean overall composite QOL score changes were computed in response to 30 questions, each scored 0 (lowest QOL) to 5 (highest QOL). Positive changes from baseline indicate improved QOL.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.61","spread":"0.827"},{"groupId":"OG001","value":"0.56","spread":"0.754"}]}]}]},{"type":"PRIMARY","title":"Mean Change From Baseline to Month 12 for Red Blood Cell Count Values","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.31","spread":"0.271"},{"groupId":"OG001","value":"-0.11","spread":"0.349"}]}]}]},{"type":"PRIMARY","title":"Mean Change From Baseline to Month 12 for Mean Corpuscular Hemoglobin Concentration Values","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.67","spread":"1.428"},{"groupId":"OG001","value":"0.56","spread":"1.277"}]}]}]},{"type":"PRIMARY","title":"Mean Change From Baseline to Month 12 for Platelet Count Values","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.7","spread":"36.24"},{"groupId":"OG001","value":"-1.9","spread":"39.31"}]}]}]},{"type":"PRIMARY","title":"Mean Change From Baseline to Month 12 for White Blood Cell Count Values","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.20","spread":"1.610"},{"groupId":"OG001","value":"0.04","spread":"1.624"}]}]}]},{"type":"PRIMARY","title":"Mean Change From Baseline to Month 12 for Blood Urea Nitrogen Values","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"4.58"},{"groupId":"OG001","value":"0.0","spread":"4.03"}]}]}]},{"type":"PRIMARY","title":"Mean Change From Baseline to Month 12 for Creatinine Values","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.04","spread":"0.323"},{"groupId":"OG001","value":"-0.04","spread":"0.111"}]}]}]},{"type":"PRIMARY","title":"Mean Change From Baseline to Month 12 for Calcium Values","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.25","spread":"0.421"},{"groupId":"OG001","value":"-0.04","spread":"0.443"}]}]}]},{"type":"PRIMARY","title":"Mean Change From Baseline to Month 12 for Inorganic Phosphorus Values","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.09","spread":"0.613"},{"groupId":"OG001","value":"0.06","spread":"0.730"}]}]}]},{"type":"PRIMARY","title":"Mean Change From Baseline to Month 12 for Total Bilirubin Values","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.02","spread":"0.166"},{"groupId":"OG001","value":"-0.01","spread":"0.170"}]}]}]},{"type":"PRIMARY","title":"Mean Change From Baseline to Month 12 for Alkaline Phosphatase Values","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"11.59"},{"groupId":"OG001","value":"-0.4","spread":"14.69"}]}]}]},{"type":"PRIMARY","title":"Mean Change From Baseline to Month 12 for Aspartate Aminotransferase Values","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"7.81"},{"groupId":"OG001","value":"0.6","spread":"10.14"}]}]}]},{"type":"PRIMARY","title":"Mean Change From Baseline to Month 12 for Alanine Aminotransferase Values","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"10.43"},{"groupId":"OG001","value":"0.5","spread":"17.43"}]}]}]},{"type":"PRIMARY","title":"Mean Change From Baseline to Month 12 for Serum Gastrin Levels","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"155.8","spread":"189.67"},{"groupId":"OG001","value":"115.4","spread":"156.32"}]}]}]},{"type":"PRIMARY","title":"Mean Change From Baseline to Month 12 for Systolic Blood Pressure","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":"15.37"},{"groupId":"OG001","value":"1.9","spread":"14.91"}]}]}]},{"type":"PRIMARY","title":"Mean Change From Baseline to Month 12 for Diastolic Blood Pressure","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":"9.53"},{"groupId":"OG001","value":"0.6","spread":"11.03"}]}]}]},{"type":"PRIMARY","title":"Mean Change From Baseline to Month 12 for Pulse Rate","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"10.11"},{"groupId":"OG001","value":"-1.3","spread":"11.87"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Month 6 for PAGI-QOL Total Score","description":"Mean overall composite QOL score changes were computed in response to 30 questions, each scored 0 (lowest QOL) to 5 (highest QOL). Positive changes from baseline indicate improved QOL.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.58","spread":"0.792"},{"groupId":"OG001","value":"0.56","spread":"0.758"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Month 9 for PAGI-QOL Total Score","description":"Mean overall composite QOL score changes were computed in response to 30 questions, each scored 0 (lowest QOL) to 5 (highest QOL). Positive changes from baseline indicate improved QOL.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.64","spread":"0.757"},{"groupId":"OG001","value":"0.60","spread":"0.811"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Month 12 for PAGI-QOL Total Score","description":"Mean overall composite QOL score changes were computed in response to 30 questions, each scored 0 (lowest QOL) to 5 (highest QOL). Positive changes from baseline indicate improved QOL.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.56","spread":"0.725"},{"groupId":"OG001","value":"0.61","spread":"0.809"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Month 1 for PAGI-SYM Total Score","description":"Mean overall composite symptom-severity score changes were computed in response to 20 questions, each scored 0 (no symptoms) to 5 (most severe symptoms). Negative changes from baseline indicate improvement in symptoms (decrease in severity).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.95","spread":"0.876"},{"groupId":"OG001","value":"-0.85","spread":"0.874"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Month 3 for PAGI-SYM Total Score","description":"Mean overall composite symptom-severity score changes were computed in response to 20 questions, each scored 0 (no symptoms) to 5 (most severe symptoms). Negative changes from baseline indicate improvement in symptoms (decrease in severity).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.09","spread":"0.913"},{"groupId":"OG001","value":"-0.91","spread":"0.896"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Month 6 for PAGI-SYM Total Score","description":"Mean overall composite symptom-severity score changes were computed in response to 20 questions, each scored 0 (no symptoms) to 5 (most severe symptoms). Negative changes from baseline indicate improvement in symptoms (decrease in severity).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.05","spread":"0.885"},{"groupId":"OG001","value":"-0.93","spread":"0.856"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Month 9 for PAGI-SYM Total Score","description":"Mean overall composite symptom-severity score changes were computed in response to 20 questions, each scored 0 (no symptoms) to 5 (most severe symptoms). Negative changes from baseline indicate improvement in symptoms (decrease in severity).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.17","spread":"0.902"},{"groupId":"OG001","value":"-0.89","spread":"0.903"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Month 12 for PAGI-SYM Total Score","description":"Mean overall composite symptom-severity score changes were computed in response to 20 questions, each scored 0 (no symptoms) to 5 (most severe symptoms). Negative changes from baseline indicate improvement in symptoms (decrease in severity).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.08","spread":"0.915"},{"groupId":"OG001","value":"-0.95","spread":"0.879"}]}]}]},{"type":"PRIMARY","title":"Changes From Baseline to Final Visit in Antrum Biopsy Results","description":"Normal=normal tissue; Unknown Baseline = Baseline biopsy not available; Abnormal diagnoses include: Reactive Gastropathy, Chronic Gastritis, Intestinal Metaplasia, Reflective Observation Mucosa-Associated Lymphoid Tissue Lymphoma, Other Abnormal.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"114","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"PRIMARY","title":"Changes From Baseline to Final Visit in Fundus Biopsy Results","description":"Normal=normal tissue; Unknown Baseline = Baseline biopsy not available; Abnormal diagnoses include: Reactive Gastropathy, Chronic Gastritis, Intestinal Metaplasia, Reflective Observation Mucosa-Associated Lymphoid Tissue Lymphoma, Other Abnormal.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55","spread":null},{"groupId":"OG001","value":"198","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":9},"commonTop":["Upper Respiratory Tract Infections","Gastrointestinal and Abdominal Pains (Excl Oral and Throat)","Nausea and Vomiting Symptoms","Diarrhoea (Excl Infective)","Headaches NEC"]}}}